Immune Deficiency

What is Common Variable Immune Deficiency (CVID)?

Common Variable Immune Deficiency and resultant disorders
Common Variable Immune Deficiency (CVID) is one of the most frequently diagnosed primary immunodeficiencies, especially in adults, characterized by low levels of serum immunoglobulins and antibodies, –which causes an increased susceptibility to infection. While CVID is thought to be due to genetic defects, the exact cause of the disorder is unknown in the large majority of cases.

What is the prevalence of CVID?

Overview of Common Variable Immune Deficiency
Compared to other human immune defects, CVID is a relatively frequent form of primary immunodeficiency, found in about 1 in 25,000 persons; this is the reason it is called “common.” The degree and type of deficiency of serum immunoglobulins, and the clinical course, varies from patient to patient, hence, the word “variable.” In some patients, there is a decrease in both IgG and IgA; in others, all three major types of immunoglobulins (IgG, IgA and IgM) are decreased

Vigoprot Powder

Vigoprot prepared by Yamuna Pharmacy is the product that gives boost to the musculo-skeltal energy and vitality

Gulvalex Capsule

Gulvalex capsule prepared by Yamuna Pharmacy is best remedy for rheumatic disorders and
promoter of immunity against various infectious diseases and keeps the body fit when taken randomly for short durations intermittently.

Product Available

Immune Deficiency

What are Clinical Features of Common Variable Immune Deficiency (CVID)?

Both males and females may have CVID. In the majority, the diagnosis is not made until the third or fourth decade of life. However, about 20% of patients have symptoms of the disease or are found to be immunodeficient in childhood. Because the immune system is slow to mature, the diagnosis of CVID is generally not made until after the age of 4.

Description

What is the prevalence of CVID?
Overview of Common Variable Immune Deficiency
Compared to other human immune defects, CVID is a relatively frequent form of primary immunodeficiency, found in about 1 in 25,000 persons; this is the reason it is called “common.” The degree and type of deficiency of serum immunoglobulins, and the clinical course, varies from patient to patient, hence, the word “variable.” In some patients, there is a decrease in both IgG and IgA; in others, all three major types of immunoglobulins (IgG, IgA and IgM) are decreased. In still others there are defects of the T-cells, and this may also contribute to increased susceptibility to infections as well as autoimmunity, granulomata and tumors.
To be sure that CVID is the correct diagnosis, there must be evidence of a lack of functional antibodies and other possible causes of these immunologic abnormalities must be excluded. Frequent and/or unusual infections may first occur during early childhood, adolescence or adult life. Patients with CVID also have an increased incidence of autoimmune or inflammatory manifestations, granulomata and an increased susceptibility to cancer when compared to the general population. Sometimes it is the presence of one of these other conditions that prompts an evaluation for CVID.
The medical terms for absent or low blood immunoglobulins are agammaglobulinemia and hypogammaglobulinemia, respectively. Due to the late onset of symptoms and diagnosis, other names that have been used in the past include “acquired” agammaglobulinemia, “adult onset” agammaglobulinemia, or “late onset” hypogammaglobulinemia. The term “acquired immunodeficiency” refers to a syndrome caused by the AIDS virus (HIV) and should not be used for individuals with CVID, as these disorders are very different.

What are Clinical Features of Common Variable Immune Deficiency (CVID)?
Both males and females may have CVID. In the majority, the diagnosis is not made until the third or fourth decade of life. However, about 20% of patients have symptoms of the disease or are found to be immunodeficient in childhood. Because the immune system is slow to mature, the diagnosis of CVID is generally not made until after the age of 4.
The usual presenting features of CVID are recurrent infections involving the ears, nasal sinuses, bronchi (breathing tubes) and lungs (respiratory tract). When the lung infections are severe and occur repeatedly, permanent damage with widening and scarring of the bronchial tree, a condition termed bronchiectasis, may develop.
The organisms commonly found in these sinopulmonary infections are bacteria that are widespread in the population and that often cause pneumonia (Hemophilus influenzae, pneumococci, and staphylococci) even in people who do not have CVID. The purpose of treatment of lung infections is to prevent their recurrence and the accompanying chronic and progressive damage to lung tissue. A regular cough in the morning and the production of yellow or green sputum may suggest the presence of chronic bronchitis or bronchiectasis.
Patients with CVID may also develop enlarged lymph nodes in the neck, the chest or abdomen. The specific cause is unknown, but enlarged lymph nodes may be caused by infection, an abnormal immune response or both. Similarly, enlargement of the spleen is relatively common, as is enlargement of Peyer’s patches which are collections of lymphocytes in the walls of the intestine.
In some cases, other collections of inflammatory cells, called granulomas, can be found in lungs, lymph nodes, liver, skin or other organs. These are largely composed of cells called monocytes and macrophages. They may be a response to an infection, but the cause is not really known.
Although patients with CVID have depressed antibody responses and low levels of immunoglobulins in their blood, some of the antibodies that are produced by these patients may attack their own tissues (autoantibodies). These autoantibodies may attack and destroy blood cells, like red cells, white cells or platelets. Although, most individuals with CVID present first with recurrent bacterial infections, in about 20% of cases the first manifestation of the immune defect is a finding of very low platelets in the blood or severe anemia due to destruction of red cells. Autoantibodies may also cause other diseases such as arthritis or endocrine disorders, like thyroid disease.
Gastrointestinal complaints such as abdominal pain, bloating, nausea, vomiting, diarrhea and weight loss are not uncommon in CVID. Careful evaluation of the digestive organs may reveal malabsorption of fat and certain sugars or inflammatory bowel disease. If a small sample (biopsy) of the bowel mucosa is obtained, characteristic changes may be seen. These changes are helpful in diagnosing the problem and treating it. In some patients with digestive problems, a small parasite called Giardia lamblia has been identified in the biopsies and in the stool samples. Eradication of these parasites by medication may eliminate the gastrointestinal symptoms.
Some patients with CVID who may not be receiving optimal immunoglobulin replacement therapy may also develop a painful inflammation of one or more joints. This condition is called polyarthritis. In the majority of these cases, the joint fluid does not contain bacteria. To be certain that the arthritis is not caused by a treatable infection; the joint fluid may be removed by needle aspiration and studied for the presence of bacteria. In some instances, a bacterium called Mycoplasma may be the cause and can be difficult to diagnose. The typical arthritis associated with CVID may involve the larger joints such as knees, ankles, elbows and wrists. The smaller joints, like the finger joints, are rarely affected. Symptoms of joint inflammation usually disappear with adequate immunoglobulin therapy and appropriate antibiotics. In some patients, however, arthritis may occur even when the patient is receiving adequate immunoglobulin replacement.
Finally, patients with CVID may have an increased risk of cancer, especially cancer of the lymphoid system or gastrointestinal tract.
Diagnosis of Common Variable Immune Deficiency
CVID should be suspected in children or adults who have a history of recurrent bacterial infections involving ears, sinuses, bronchi and lungs. The characteristic laboratory features include low levels of serum immunoglobulins, including IgG, often IgA and sometimes IgM. Another part of the diagnosis of CVID is to determine if there is a lack of functional antibody. This is done by measuring serum levels of antibody, against vaccine antigens such as tetanus or diphtheria, measles, mumps, or rubella, hemophilus or pneumococcal polysaccharide. Patients with CVID have very low or absent antibody levels to most of these vaccines.
Immunization with killed vaccines is used to measure antibody function, and this functional testing is crucial prior to beginning treatment. These tests also help the physician decide if the patient will benefit from immunoglobulin replacement therapy. The number of B- and T-lymphocytes may also be determined and their function tested in tissue cultures.
A few symptoms and ailments included in immunodeficiency are: Sinusitis, Frequently catching of bad cold ,Chronic coughing. Recurring diarrheas, Malabsorption syndrome ,
Unresponsiveness to anti-infective therapy, Skin allergies, Respiratory allergies etc.

Treatment of Common Variable Immune Deficiency
and general wellbeing & good health

Vigoprot powder Gulvalex capsule from Yamuna Pharmacy are the two products that tend to improvingly change the health of Common Variable Immune Deficiency (CVID) patients and give strengthening boost to combat recurrent infections of respiratory system,musculo-skeltal system and digestive system augmenting energy and vitality.

How Vigoprot powder and Gulvalex capsule are helpful to contain immunodeficiency and its impacts?

Vigoprot powder promotes the growth in children and Gulvalex capsule protects and prevents from progression of rheumatism.
Vigoprot acts as Immunity Booster thus helpful to build the strength to resist various infectious diseases and fight free radicals that cause frequently occurring bad cold and coughs.
Gulvalex capsule stops swellings and inflammations of tissues, cartilages and joints thus controlling pain in muscles, bones and joints.
Gulvalex capsule has a balancing effect on physical temperature thus useful in fevers with infections or tiredness.

What are the ingredients in Vigoprot?

Vigoprot comprises concentrated herbal extracts of Ashwagandha,Shatawari,Amalki and Shankhpushpi(physical and mental health boosters) alongwith Khatika (calcium provider) wheymilk and skimmed milk.
How the beverage of Vigoprot is prepared and used?

1) Take a mug of lukewarm or cold milk
2) Add 2-3 heaped tablespoons of Vigoprot
3) Stir and drink with or without sugar as per requirement

Who is behind concept of formulation of Vigoprot?

Vigoprot is conceived and formulated by expert team of G.A.M.S,B.Pharm (Ay)and MSc (Med.Botany) personnels

What other benefits one gets from Gulvalex capsule?

Gulvalex capsule also imparts preventive and curative & anti-inflammatory relief by supporting other specific medicines in:

*Rheumatism, Rheumatoid arthritis       *ENT diseases
* Gout       *Diabetes
* Febrile and post febrile conditions       *Sciatica
*Frozen shoulder       *Comprehensive anemia
*Backache       *Dermatology
*Tender and swollen joints       *Andrlogy and Gynaecology
* Numbness of skin       *General surgery
*Morning stiffness that may last for couple of hours       *Fatigue – mental and physical
* Imbalanced weight gain with Lipolyt capsule       *In weight loss with
Vigoprot powder

What is the composition of Gulvalex capsule?

Gulvalex capsule comprises extract of Tinospora cordifolia as per approved strength.

What is the dose of Gulvalex capsule?

1 to 2 capsules twice or thrice a day till satisfactory feel good experience followed by 1 capsule twice a day as maintenance therapy.

Who is behind concept of formulation of Gulvalex capsule?

Gulvalex capsule is conceived and formulated by expert team of GAMS,B.Pharm (Ay)and MSc (Med.Botany) and BAMS personnels